Related Experiment Video
Updated: May 20, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Rifampicin and Parkinson's disease
Wei Bi1, Lihong Zhu, Xiuna Jing
1Department of Neurology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, People's Republic of China.
Summary
Rifampicin, an antibiotic, shows neuroprotective effects by protecting neurons from cell death and inflammation. This suggests its potential as a therapeutic agent for Parkinson's disease (PD) treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Cell Biology
Background:
- Rifampicin is a known antibiotic for mycobacterial infections.
- Emerging evidence suggests rifampicin possesses neuroprotective properties.
- Parkinson's disease (PD) involves neurodegeneration and inflammation.
Purpose of the Study:
- To review experimental data on rifampicin's neuroprotective effects.
- To investigate the molecular and cellular mechanisms of rifampicin's cytoprotective actions.
- To explore rifampicin's potential as a therapeutic for Parkinson's disease.
Main Methods:
- In vitro studies using PC12 cells.
- Exposure to neurotoxic agents like MPP(+) and rotenone.
- Analysis of apoptosis, mitochondrial oxidative stress, and microglial inflammation.
Main Results:
- Rifampicin pretreatment protected PC12 cells against MPP(+) and rotenone-induced cell death.
- Rifampicin ameliorated mitochondrial oxidative stress and suppressed apoptosis.
- It was observed to reduce microglial inflammation and enhance neuron survival.
Conclusions:
- Rifampicin demonstrates significant cytoprotective effects in in vitro models.
- Its mechanisms involve mitigating oxidative stress and inflammation.
- Rifampicin shows promise as a potential therapeutic agent for Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).